2022 looks set to be another busy year for the psychedelics space, with a number of late-stage clinical trials commencing or wrapping

What credentials will likely be necessary to legally provide psychedelic therapy?

The purpose of this Primer is to provide those interested in the field of psychedelics with a concise and accessible overview of the scientific data.

Symptom reduction following ketamine infusions in severely ill patients suggest that ketamine, despite being inferior to ECT, can be a safe and valuable tool .

The Innovative Licensing and Access Pathway (ILAP) Innovation Passport has ben granted to MDMA as an adjunct to therapy for posttraumatic stress disorder (PTSD) in the United Kingdom (UK).

This review examines the positive and negative aspects of different formulations and routes of administration of DMT

Development of meaning-creating psychotherapies and further research findings in psychedelic therapies may contribute to more compassionate and mindful care.

Suicide is a global health concern, and innovative interventions that target suicidality are needed.

The present research aimed to uncover an emerging model of MDMA use grounded in the experiences of adult couples using MDMA privately and in the context of their committed relationships.

This study compared five psychedelic substance report groups and a non-psychedelic report group on quantitative linguistic markers.

Exactly fifty years after the ban on psychedelics a group of Zen meditators – who have never used any psychedelic substances before – are given psilocybin on the last day of a 5-day retreat. Half the group receives a placebo.

There are neurophysiological and phenomenological overlaps between psychedelic and meditative states, but there is little evidence on how exposure to psychedelics might be associated with meditation-related variables. We assessed lifetime classic psychedelic use, ego dissolution during one's most intense experience using a classic psychedelic, and exposure to meditation in a representative sample (n = 953) of American adults.

The resurgence of research into psychedelics has continued to thrive over the past year. Dozens of trials and hundreds of studies have been published in 2021.

Ketamine treatment was well tolerated and was also helpful.

Results revealed that lifetime MDMA/ecstasy and/or psilocybin use were associated with significantly lowered odds of a lifetime MDE ... and past year severe MDE.

These results indicate that 10 mg and 25 mg doses of psilocybin were generally well tolerated when given to up to six participants simultaneously ...

The published data suggest that ibogaine is an effective therapeutic intervention within the context of SUDs, reducing withdrawal symptoms and craving.

A significant number of Americans are already “self-medicating” with PM

Our randomised controlled phase IIb study of psilocybin therapy in treatment-resistant depression is the largest psilocybin therapy clinical trial ever conducted

Two recent studies raise the exciting possibility that it could be both safe and helpful to add psilocybin-assisted therapy to SSRI's.